Liprolog Kwikpen (Insulin Lispro)

Insulin lispro quickly binds to insulin receptors on muscle and fat cells, prompting the movement of GLUT‑4 transporters to the cell surface. This accelerates glucose uptake from the bloodstream and suppresses liver glucose production, resulting in a rapid decline in blood glucose levels after injection.

The dose of insulin lispro is individualized. A prescriber determines the amount based on the patient’s weight, carbohydrate intake, current blood glucose levels, and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical guidance.

Insulin lispro is classified as a pregnancy category that may be used when the benefits outweigh potential risks. It is generally considered safe for pregnant women with diabetes when closely monitored. Limited data exist for breastfeeding, but insulin is usually compatible; however, a physician should evaluate each case.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Liprolog Kwikpen (insulin lispro) has a rapid onset of action similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine. All provide quick glucose control after meals, but subtle differences in pharmacokinetics may influence individual dosing schedules. Choice often depends on physician preference, patient response, and device convenience.

Store Liprolog Kwikpen in a refrigerator at 2‑8 °C (36‑46 °F). Keep the pen in its original carton, protect it from light, and avoid freezing. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but should not be exposed to extreme heat or direct sunlight.

Liprolog Kwikpen is a pre‑filled pen injector designed for subcutaneous injection. After washing hands, the user selects the prescribed dose, attaches a new needle, and injects into the abdomen, thigh, or upper arm at a 90‑degree angle. Proper site rotation and technique are essential to ensure consistent absorption.

The most serious risks include severe hypoglycemia, which can cause seizures, loss of consciousness, or accidents, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a severe reaction occurs.

Liprolog Kwikpen should not be used by individuals with a known hypersensitivity to insulin lispro or any of the pen’s excipients. It is also contraindicated in patients experiencing hypoglycemia at the time of injection. Clinicians should assess each patient’s medical history before initiating therapy.